ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AVCT Avacta Group Plc

49.75
0.75 (1.53%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Avacta Group Plc LSE:AVCT London Ordinary Share GB00BYYW9G87 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.75 1.53% 49.75 3,399,639 16:13:35
Bid Price Offer Price High Price Low Price Open Price
49.50 50.00 49.75 47.50 48.75
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 10.06M -39.19M -0.1382 -3.60 141.1M
Last Trade Time Trade Type Trade Size Trade Price Currency
16:30:59 O 250,000 48.398 GBX

Avacta (AVCT) Latest News (1)

Avacta (AVCT) Discussions and Chat

Avacta (AVCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-03-28 16:31:0048.40250,000120,995.00O
2024-03-28 16:29:3549.821,000498.15O
2024-03-28 16:28:5249.81347172.85O
2024-03-28 16:28:1449.8118491.66O
2024-03-28 16:27:0549.81199.46O

Avacta (AVCT) Top Chat Posts

Top Posts
Posted at 29/3/2024 08:20 by Avacta Daily Update
Avacta Group Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker AVCT. The last closing price for Avacta was 49p.
Avacta currently has 283,614,110 shares in issue. The market capitalisation of Avacta is £141,098,020.
Avacta has a price to earnings ratio (PE ratio) of -3.60.
This morning AVCT shares opened at 48.75p
Posted at 28/3/2024 08:27 by hamidahamida
Placing happy loss making companies Share price always collapses to half of placing priceFact check 2022 placing at 95pToday Sp under 50p Last placing at 50p Fully expecting share price to collapse to 25p Always happens
Posted at 29/2/2024 16:30 by pwhite73
There is sufficient liquidity for the bonds to have zero effect on the share price. The term date for the bonds is 5 years and conversion is quarterly. That's 20 payments over five years. £55 million divided by 20 is £2.75 million per quarter.

£2.75 million divided by 90 days is on average £31,000 per day. Look at the volume per day for AVCT. The share price decline has nothing to do with the bonds its the inability of the shares to gain traction on the clinical trial results.
Posted at 29/2/2024 15:21 by pwhite73
Aman - "A reminder - convis kill companies."

Wrong again. AVCT do not have a death spiral in place.

The CLN was announced in October 2022 when the share price was at 119p. The share price peaked to 186p in February 2023. It dropped to 95p in July 2023 and rose to 150p in October 2023.

There is no correlation between the conversions and the share price.

What has gone wrong here is that the share price has failed to respond to the progress the company claims AVA6000 is making. The reasons I have given a million times.

It is a mistake to blame the CLN for the decline in the share price.
Posted at 29/2/2024 12:07 by jaknife
loglorry1,

===========================
"EG At what price do the bonds reset. Obviously that was part of the original deal but not shared hence many saw 95P as the floor."

I think they will reset down at some discount to VWAP probably around 40p. Their will be anti-dilution clauses and other clauses they didn't disclose.
===========================

There was a comment about this in the placing notice:


===========================
Unsecured Convertible Bonds

In October 2022, the Group issued senior unsecured convertible bonds (the "Bonds") of £55.00 million in aggregate principal amount to a fund advised by Heights Capital Ireland LLC ("Heights"). The Bonds were issued at 95% par value resulting in total gross cash proceeds of £52.25 million with a 6.5 per cent. coupon and amortise quarterly at 5 per cent. of the initial principal amount, with an initial 25 per cent. conversion premium to the offer price and a five-year term.

The Bonds were issued with a five-year term and are repayable in 20 quarterly amortisation repayments of principal and interest in either cash or in new Shares at the Group's option. If paid in new Shares, the repayment is at the lower of the initial conversion price (118.75 pence) or a 10 per cent. discount to the volume weighted average price ("VWAP") in the five- or ten-day trading period prior to each election date. The Bonds contain various conversion and redemption features together with standard UK market anti-dilution features.

As a result of the Offer Price being less than 95 per cent. of the VWAP in the five-day trading period prior to the announcement of the Placing, the Direct Subscription and the REX Offer, the conversion price (118.75 pence) and the reset floor price (95 pence) will be recalculated by the calculation agent using an adjustment factor calculation as follows:

1. the adjustment factor will be (A+B)/(A+C), where:

1. A = number of Shares in issue immediately before the date of first public announcement of the terms (the "Pricing Date") of the Bookbuild;

2. B = aggregate gross proceeds of the Bookbuild divided by the Current Market Price ("CMP") on the Pricing Date of the Bookbuild, where CMP on the Pricing Date = arithmetic average of the five daily VWAPs immediately preceding the Pricing Date; and

3. C = number of Shares comprised in the Bookbuild.

The principal remaining under the Bonds was reduced by a further £2.55 million to £38.25 million on 22 January 2024 following the fifth quarterly amortisation.

From:
===========================


This is a more generous version of the typical reset clause and should see the price set above 50p (but below 95p).

JakNife
Posted at 27/2/2024 07:29 by amanitaangelicus
Nasdaq ? Just seen a Welsh Saddleback flying over my vegetable garden. Today is rather important. We need to see where the convi reset price is. The insiders and convi boys know - they.ve just been positioning , resetting as of late. Of course, this could be incorrect. If a licensing deal has been struck( or serious discussions begun) the share price would be up at 120-130p plus, depending on what revenue/ resulting profit has been sacrificed. share price bouncing all over. Very difficult to read. Binary at this point in time. GLA.
Posted at 22/2/2024 09:54 by fieldhouse
So, the share price drops to 50p. £30 million raised to take through phase 2.
Uncertainty goes and dose escalation progresses well with good data from C7.
Two weekly dosing progresses in the US.

Worries all gone ---- Share price and company do have a paradigm shift.

A lot of money in the mean time transferred to the soothsayer's

QED
Posted at 15/2/2024 19:10 by tickboo
Hi Log, yep the share price here disappointing for holders. That said, aside from a few months in 2022 we have been between 87p to 140p for over 3 years. I would of course like to be a lot higher than where we sit but I am not worried.We will need to raise cash I would think by March or latest end of April and certainly before their accounts are signed off. The recalculation for the CLNs take place end of April so if it isn't sorted regardless of data the share price will tank so yes they'd be much more confetti and death spiral will happen for sure (ever subsequent strike price lower so more shares issued each Q). I firmly believe there will be sufficient cash before second week in April (due to recalculation) and it won't be through retail. The comms here shocking but I think we'll be more than fine. I'm looking forward to AACR and am certain we will have some amazing results. Not long to find out old chap.
Posted at 22/1/2024 12:40 by ohwhatfun
Tick Yes cash needed and plenty of it if phase 2 is to be in play.

TGR saw a recent raise just a 10% or discount (so the news says) but 10% from the previous day the market took it well down prior.

It’s all very honest in the market, typically a couple of weeks notice for a raise, with two weeks of the inner circle (secure as a sieve) knowing.

Yet on just about every occasion share prices mysteriously take a dive contradicting apparent reported buys/sells.

So if a go to market raise comes, it will soon be obvious by the share price action, which will differ to the chart current downtrend.

Based on typical market behaviour which is not a nice place to seek backing in recent times.
Posted at 21/1/2024 07:26 by tickboo
A conversion RNS on Monday, conversion likely to be around 95p so lower than the last although around the same price as raise. Question is will the share price be put under pressure. Only 1 of the last 4 quarterly conversions resulted in a falling share price after (July conversion). The share price has tended to increase after one. That said we know cash will be sought likely before Easter. Question is will it be through licensing deals or dilutive? That will be key as will the April conversion where the prices can be re-set. Cohorts 6 and 7 data due and we have AACR so I suspect Avacta will present the new data there. Fortnightly will surely dose soon. I doubt Chris would have joined a sinking ship in a full-time role and one suspects she has bought in to the tech. An interesting and pivotal few months ahead. Always DYOR and if invest do so with what you are comfortable with.
Posted at 14/12/2023 07:35 by tickboo
Rah on X-Digesting the reaction to yesterday's PK is even more absurd in the cold light of day. #AVCT has:- demonstrated unequivocally that preCISION works;- delivered Dox into the tumour in a highly specific way, sparing healthy tissue in the process, solving a 50 yr old problem in the process;- shown a 65% reduction in a patient with STS, who would not be expected to live, let alone remain on drug for 15 months as is their expectation;- demonstrated other refractory cancers are showing a halting of progression and/or shrinkage.Dox is being dox. But much, much safer. It's the exact problem AVCT set out to solve before the trial began 856 days ago when the share price sat at 124p.We should be sat at ATHs right now. The product works. The platform works.Why aren't we? The CEO opted to shy away from every question on funding, beyond confirmation we will not seek to partner our lead asset til P2 (sensible).It's quite clear there is tons going on right now which AVCT simply refuse to talk to.The conversations which were happening in June ('deal value discussions') haven't just gone way; Novartis employees aren't publicly lauding our achievement to be nice; the CEO didn't utter a word on funding because it slipped his mind.AVCT will next take a working drug and dose on a a bi-weekly basis. Dox will be dox. And dox is the 40yr old standard of care in STS. How do you think Dox will perform when placed in patients via a 1st line setting? It will do as Dox always does.AVCT will not require a dox comparison arm in Phase 2. Avacta will skip Phase 1b. They will seek Accelerated Approval. We know how Dox works. We know we can deliver it safely. We know Pharma is watching.The share price has fallen from 124p > 118p over this period.Few doubts given all of the above a deal lands, independently verifying the platform. When that occurs the whiplash will be severe.I'm not saying the CEO's ambivalence to the share price is acceptable. It's not. I'm saying I think he has something up his sleeve which rendered him almost horizontal in his confidence. Good luck if you're playing 7am roulette with a working platform, backed by 850+ days of data. A risky time to be doing that.
Avacta share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock